Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 in Acutely Psychotic Patients with Schizophrenia
jRCT2071210003Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ulotaront in schizophrenia (3 arms), sponsored by Sumitomo Pharma. Primary endpoint: Change from baseline in PANSS total score at Week 6. Started Mar 2021; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2071210003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210003.